Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Conference Call February 8, 2024 8:30 AM ET

Company Participants

Diantha Duvall - Chief Financial Officer

Jim Dentzer - President & Chief Executive Officer

Jonathan Zung - Chief Development Officer

Conference Call Participants

Ed White - H.C. Wainwright

Soumit Roy - JonesTrading

Li Watsek - Cantor Fitzgerald

Yale Jen - Laidlaw & Company

Operator

Good morning, and welcome to Curis' Fourth Quarter 2023 Business Update Call. All participants will be in a listen-only mode. [Operator Instructions] After the company's prepared remarks, all participants will have an opportunity to ask questions. [Operator Instructions] Please note that this event is being recorded.

I would now like to turn the conference over to Diantha Duvall, Curis' Chief Financial Officer. Diantha, please go ahead.

Diantha Duvall

Thank you, and welcome to Curis' fourth quarter 2023 business update call. Before we begin, I would like to encourage everyone to go to our Investors section of our website at www.curis.com to find our fourth quarter 2023 business update release and related financial tables.

I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings.

Joining me on today's call are Jim Dentzer, President and Chief Executive Officer; and Jonathan Zung, Chief Development Officer. We will also be available for a question-and-answer period at the end of our call.

I'd like to -- I'd now like to turn the call over to Jim. Jim?

Jim Dentzer

Thank you. Thank you, Diantha. Good morning, everyone, and welcome to Curis' fourth quarter business update call.

I'd like to start today's call with a look back over the past 12 months. Entering 2023, the whole biotech industry was struggling in the headwinds of a green financial market. Curis faced all of that and the daunting challenge of seeing our leukemia study stalled on partial clinical hold with the FDA.

In the face of that adversity, the Curis team rose to the challenge. We worked tirelessly in answering questions posed by the FDA. This included enrolling additional patients at 200 milligrams BID and performing additional analyses. As a result, we were able to confirm the safety profile of emavusertib, gain alignment on the optimal dosing regimen for monotherapy and secure the removal of the partial clinical hold, a full quarter earlier than expected.